InflaRx N.V. (NASDAQ: IFRX) received a deficiency notice from NASDAQ on March 11, 2026, indicating its share price closed below the required $1.00 minimum for 30 consecutive business days, according to a company statement.

The biopharmaceutical company has 180 calendar days until September 7, 2026, to regain compliance with NASDAQ's minimum bid price requirement under Listing Rule 5450(a)(1). If unsuccessful, InflaRx may apply to transfer from the NASDAQ Global Select Market to the NASDAQ Capital Market, potentially providing an additional 180 days until March 8, 2027, to meet the requirement.

The notice does not immediately affect the listing or trading of InflaRx's ordinary shares. The company stated it will monitor its share price and consider available options to regain compliance.

InflaRx develops anti-inflammatory therapeutics targeting the complement system. The company's lead program is izicopan, an oral small molecule inhibitor for inflammatory diseases including hidradenitis suppurativa. InflaRx also developed vilobelimab, an intravenous anti-C5a monoclonal antibody.

The company, founded in 2007, maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan. InflaRx operates through wholly owned subsidiaries InflaRx GmbH in Germany and InflaRx Pharmaceuticals Inc. in the United States.